Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1
暂无分享,去创建一个
L. Zitvogel | O. Kepp | G. Kroemer | C. Lefebvre | P. Laurent-Puig | E. Vacchelli | I. Vitale | M. Ducreux | F. André | G. Stoll | J. M. Bravo-San Pedro | C. Borg | D. Enot | V. Boige | S. Delaloge | T. Ulas | J. Schultze | M. Signore | S. Ladoire | Patrick Günther | C. Delarasse | L. Businaro | A. Gerardino | F. Mattei | G. Schiavoni | C. Mulot | G. Manic | A. Sistigu | S. Rusakiewicz | M. Semeraro | K. Chaba | L. Apetoh | Yuting Ma | H. Yang | F. Pietrocola | S. Adjemian | F. Castoldi | M. Lucattelli | A. De Ninno | V. Lucarini | Francesca Peschiaroli | E. E. Baracco | Sandy Adjemian | Kariman Chaba | Erika Vacchelli
[1] L. Zitvogel,et al. Natural and therapy-induced immunosurveillance in breast cancer , 2015, Nature Medicine.
[2] Tingting Li,et al. FAM19A4 is a novel cytokine ligand of formyl peptide receptor 1 (FPR1) and is able to promote the migration and phagocytosis of macrophages , 2014, Cellular and Molecular Immunology.
[3] Sebastian Amigorena,et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. , 2014, Cancer cell.
[4] M. Delorenzi,et al. Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy , 2014, Nature Medicine.
[5] G. Marone,et al. The formyl peptide receptor 1 exerts a tumor suppressor function in human gastric cancer by inhibiting angiogenesis , 2014, Oncogene.
[6] A. Sklan. Lymphocytes prognostic in breast cancer. , 2014, The Lancet. Oncology.
[7] L. Zitvogel,et al. CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. , 2014, Cancer research.
[8] Sebastian Amigorena,et al. Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity. , 2014, Cancer cell.
[9] L. Zitvogel,et al. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. , 2013, Immunity.
[10] P. van Endert,et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. , 2013, Immunity.
[11] Laurence Zitvogel,et al. Immunogenic cell death in cancer therapy. , 2013, Annual review of immunology.
[12] D. Ye,et al. Molecular biology for formyl peptide receptors in human diseases , 2013, Journal of Molecular Medicine.
[13] Annamaria Gerardino,et al. Cross talk between cancer and immune cells: exploring complex dynamics in a microfluidic environment. , 2013, Lab on a chip.
[14] E. Sugar,et al. Reporting of preclinical tumor-graft cancer therapeutic studies , 2012, Cancer biology & therapy.
[15] D. C. Cara,et al. Chemokines and mitochondrial products activate neutrophils to amplify organ injury during mouse acute liver failure , 2012, Hepatology.
[16] Ming Li,et al. An Immunosurveillance Mechanism Controls Cancer Cell Ploidy , 2012, Science.
[17] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[18] Johannes E. Schindelin,et al. Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.
[19] Kevin W Eliceiri,et al. NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.
[20] H. Miettinen. Regulation of Human Formyl Peptide Receptor 1 Synthesis: Role of Single Nucleotide Polymorphisms, Transcription Factors, and Inflammatory Mediators , 2011, PloS one.
[21] Jacob D. Jaffe,et al. Mutations in MTFMT underlie a human disorder of formylation causing impaired mitochondrial translation. , 2011, Cell metabolism.
[22] P. Kubes,et al. Intravascular Danger Signals Guide Neutrophils to Sites of Sterile Inflammation , 2010, Science.
[23] M. Loriot,et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] L. Zitvogel,et al. Decoding Cell Death Signals in Inflammation and Immunity , 2010, Cell.
[25] X. Bian,et al. The G-protein-coupled formylpeptide receptor FPR confers a more invasive phenotype on human glioblastoma cells , 2010, British Journal of Cancer.
[26] Carsten Denkert,et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] J. Tschopp,et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors , 2009, Nature Medicine.
[28] Montgomery Slatkin,et al. Linkage disequilibrium — understanding the evolutionary past and mapping the medical future , 2008, Nature Reviews Genetics.
[29] L. Zitvogel,et al. Trial watch , 2012, Nature Reviews Cancer.
[30] Laurence Zitvogel,et al. Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.
[31] C. Wennerås,et al. Cyclosporin H, Boc-MLF and Boc-FLFLF are Antagonists that Preferentially Inhibit Activity Triggered Through the Formyl Peptide Receptor , 2007, Inflammation.
[32] Sebastian Amigorena,et al. In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor , 2007, The Journal of experimental medicine.
[33] These authors contributed equally to this work. , 2007 .
[34] R. Tibshirani,et al. On testing the significance of sets of genes , 2006, math/0610667.
[35] E. Demidenko. The assessment of tumour response to treatment , 2006 .
[36] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[37] Martin Kuiper,et al. BiNGO: a Cytoscape plugin to assess overrepresentation of Gene Ontology categories in Biological Networks , 2005, Bioinform..
[38] S. Lockett,et al. Identification of Neutrophil Granule Protein Cathepsin G as a Novel Chemotactic Agonist for the G Protein-Coupled Formyl Peptide Receptor 12 , 2004, The Journal of Immunology.
[39] R. Seifert,et al. The human formyl peptide receptor as model system for constitutively active G-protein-coupled receptors. , 2003, Life sciences.
[40] K. Wenzel-Seifert,et al. Functional differences between human formyl peptide receptor isoforms 26, 98, and G6 , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.
[41] D. McDermott,et al. Contrasting evolution of the human leukocyte N-formylpeptide receptor subtypes FPR and FPRL1R , 2001, Genes and Immunity.
[42] Y. Benjamini,et al. More powerful procedures for multiple significance testing. , 1990, Statistics in medicine.